US2009191215A1PendingUtilityA1

Treatment with anti-VEGF Antibodies

69
Assignee: GENENTECH INCPriority: May 30, 2003Filed: Mar 31, 2009Published: Jul 30, 2009
Est. expiryMay 30, 2023(expired)· nominal 20-yr term from priority
Inventors:Gwendolyn FyfeEric HolmgrenRobert D. MassWilliam Novotny
A61P 9/00A61P 35/04A61P 31/00A61P 43/00A61P 35/00A61P 35/02C07K 2317/565A61K 31/519A61K 38/50C07K 2317/24A61K 31/4745A61K 31/4545A61K 2039/505A61K 31/337A61K 45/06A61K 31/7068A61K 39/395A61K 9/0019A61K 39/39558A61K 31/522A61K 31/513A61K 31/282C07K 2317/21A61K 39/39541A61K 31/555A61K 31/525A61K 38/09A61K 31/573C07K 2317/567A61K 38/212C07K 16/22A61K 39/3955C07K 16/3046C07K 2317/76
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.

Claims

exact text as granted — not AI-modified
1 . A kit for treating metastatic colorectal cancer in a human patient comprising a package comprising bevacizumab and instructions for using the bevacizumab in combination with IFL (irinotecan, 5-fluorouracil and leucovorin), wherein the instructions further comprise  FIG. 1 . 
   
   
       2 . A kit for treating metastatic colorectal cancer in a human patient comprising a package comprising bevacizumab and instructions for using the bevacizumab in combination with IFL, wherein the instructions recite that the medium survival for patients receiving IFL and bevacizumab is 20.3 months with a hazard ratio of 0.66. 
   
   
       3 . A kit for treating metastatic colorectal cancer in a human patient comprising a package comprising bevacizumab and instructions for using bevacizumab in combination with IFL, wherein the instructions recite that the progression free survival for patients receiving IFL and bevacizumab is 10.6 months with a hazard ratio of 0.54. 
   
   
       4 . A kit for treating metastatic colorectal cancer in a human patient comprising a package comprising bevacizumab and instructions for using bevacizumab in combination with IFL, wherein the instructions recite that the median duration of response for patients receiving IFL and bevacizumab is 10.4 months. 
   
   
       5 . A kit for treating a cancer patient comprising a package comprising bevacizumab and instructions for using bevacizumab in combination with at least one chemotherapeutic agent, wherein the instructions provide information about the risk of gastrointestinal perforation during treatment with the anti-VEGF antibody composition. 
   
   
       6 . The kit of any one of  claims 1 - 5 , wherein the patient is previously untreated.

Join the waitlist — get patent alerts

Track US2009191215A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.